Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas

Massimo Raimondo, Issei Tachibana, Raul Urrutia, Lawrence J. Burgart, Eugene P. DiMagno

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

OBJECTIVES: Intraductal papillary mucinous tumor (IPMT) is frequently associated with pancreatic cancer. We hypothesized that IPMT progresses to invasive cancer with K-ras mutations as an early event, and that invasive cancer affects survival. We compared survival after resection and determined whether K-ras mutations predicted survival in IPMT patients without or with invasive cancer. METHODS: Records of 47 patients with IPMT who were seen between 1983 and 1998 were reviewed retrospectively in 15 cases and prospectively in 32. All histological material was reviewed to confirm the diagnosis of IPMT and to assess invasion. Kaplan-Meier survival curves were analyzed by the log-rank test. The X2 test was used for differences in K-ras between groups. RESULTS: There were 30 men and 17 women, with a mean age of 65 yr (range 36-90 yr). Of the patients, 26 had IPMT without invasive cancer and 19 had IPMT with invasion. Tissue diagnosis was available in 45 patients. K-ras was analyzed in 40 patients. Mutations were present in 15 of 23 patients (65%) without invasive cancer and in 14 of 17 patients (82%) with invasive cancer (p = ns). At 2.5 yr, the overall cumulative survival of IPMT patients without invasive cancer was 94% compared to 24% of patients with invasive cancer (p < 0.001). The 5-yr survival of IPMT patients without invasive cancer was 94%. K-ras mutations did not correlate with survival. CONCLUSIONS: Invasive cancer in IPMT reduces the 2.5-yr survival after surgery from 93% to 24%. K-ras mutations occur before invasive cancer, and do not predict postoperative survival.

Original languageEnglish (US)
Pages (from-to)2553-2558
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume97
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

Pancreas
Survival
Neoplasms
Mutation
Kaplan-Meier Estimate
Pancreatic Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. / Raimondo, Massimo; Tachibana, Issei; Urrutia, Raul; Burgart, Lawrence J.; DiMagno, Eugene P.

In: American Journal of Gastroenterology, Vol. 97, No. 10, 01.10.2002, p. 2553-2558.

Research output: Contribution to journalArticle

Raimondo, Massimo ; Tachibana, Issei ; Urrutia, Raul ; Burgart, Lawrence J. ; DiMagno, Eugene P. / Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. In: American Journal of Gastroenterology. 2002 ; Vol. 97, No. 10. pp. 2553-2558.
@article{d98a1dc5d5374bb9981356290b789d93,
title = "Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas",
abstract = "OBJECTIVES: Intraductal papillary mucinous tumor (IPMT) is frequently associated with pancreatic cancer. We hypothesized that IPMT progresses to invasive cancer with K-ras mutations as an early event, and that invasive cancer affects survival. We compared survival after resection and determined whether K-ras mutations predicted survival in IPMT patients without or with invasive cancer. METHODS: Records of 47 patients with IPMT who were seen between 1983 and 1998 were reviewed retrospectively in 15 cases and prospectively in 32. All histological material was reviewed to confirm the diagnosis of IPMT and to assess invasion. Kaplan-Meier survival curves were analyzed by the log-rank test. The X2 test was used for differences in K-ras between groups. RESULTS: There were 30 men and 17 women, with a mean age of 65 yr (range 36-90 yr). Of the patients, 26 had IPMT without invasive cancer and 19 had IPMT with invasion. Tissue diagnosis was available in 45 patients. K-ras was analyzed in 40 patients. Mutations were present in 15 of 23 patients (65{\%}) without invasive cancer and in 14 of 17 patients (82{\%}) with invasive cancer (p = ns). At 2.5 yr, the overall cumulative survival of IPMT patients without invasive cancer was 94{\%} compared to 24{\%} of patients with invasive cancer (p < 0.001). The 5-yr survival of IPMT patients without invasive cancer was 94{\%}. K-ras mutations did not correlate with survival. CONCLUSIONS: Invasive cancer in IPMT reduces the 2.5-yr survival after surgery from 93{\%} to 24{\%}. K-ras mutations occur before invasive cancer, and do not predict postoperative survival.",
author = "Massimo Raimondo and Issei Tachibana and Raul Urrutia and Burgart, {Lawrence J.} and DiMagno, {Eugene P.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0002-9270(02)04380-0",
language = "English (US)",
volume = "97",
pages = "2553--2558",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas

AU - Raimondo, Massimo

AU - Tachibana, Issei

AU - Urrutia, Raul

AU - Burgart, Lawrence J.

AU - DiMagno, Eugene P.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - OBJECTIVES: Intraductal papillary mucinous tumor (IPMT) is frequently associated with pancreatic cancer. We hypothesized that IPMT progresses to invasive cancer with K-ras mutations as an early event, and that invasive cancer affects survival. We compared survival after resection and determined whether K-ras mutations predicted survival in IPMT patients without or with invasive cancer. METHODS: Records of 47 patients with IPMT who were seen between 1983 and 1998 were reviewed retrospectively in 15 cases and prospectively in 32. All histological material was reviewed to confirm the diagnosis of IPMT and to assess invasion. Kaplan-Meier survival curves were analyzed by the log-rank test. The X2 test was used for differences in K-ras between groups. RESULTS: There were 30 men and 17 women, with a mean age of 65 yr (range 36-90 yr). Of the patients, 26 had IPMT without invasive cancer and 19 had IPMT with invasion. Tissue diagnosis was available in 45 patients. K-ras was analyzed in 40 patients. Mutations were present in 15 of 23 patients (65%) without invasive cancer and in 14 of 17 patients (82%) with invasive cancer (p = ns). At 2.5 yr, the overall cumulative survival of IPMT patients without invasive cancer was 94% compared to 24% of patients with invasive cancer (p < 0.001). The 5-yr survival of IPMT patients without invasive cancer was 94%. K-ras mutations did not correlate with survival. CONCLUSIONS: Invasive cancer in IPMT reduces the 2.5-yr survival after surgery from 93% to 24%. K-ras mutations occur before invasive cancer, and do not predict postoperative survival.

AB - OBJECTIVES: Intraductal papillary mucinous tumor (IPMT) is frequently associated with pancreatic cancer. We hypothesized that IPMT progresses to invasive cancer with K-ras mutations as an early event, and that invasive cancer affects survival. We compared survival after resection and determined whether K-ras mutations predicted survival in IPMT patients without or with invasive cancer. METHODS: Records of 47 patients with IPMT who were seen between 1983 and 1998 were reviewed retrospectively in 15 cases and prospectively in 32. All histological material was reviewed to confirm the diagnosis of IPMT and to assess invasion. Kaplan-Meier survival curves were analyzed by the log-rank test. The X2 test was used for differences in K-ras between groups. RESULTS: There were 30 men and 17 women, with a mean age of 65 yr (range 36-90 yr). Of the patients, 26 had IPMT without invasive cancer and 19 had IPMT with invasion. Tissue diagnosis was available in 45 patients. K-ras was analyzed in 40 patients. Mutations were present in 15 of 23 patients (65%) without invasive cancer and in 14 of 17 patients (82%) with invasive cancer (p = ns). At 2.5 yr, the overall cumulative survival of IPMT patients without invasive cancer was 94% compared to 24% of patients with invasive cancer (p < 0.001). The 5-yr survival of IPMT patients without invasive cancer was 94%. K-ras mutations did not correlate with survival. CONCLUSIONS: Invasive cancer in IPMT reduces the 2.5-yr survival after surgery from 93% to 24%. K-ras mutations occur before invasive cancer, and do not predict postoperative survival.

UR - http://www.scopus.com/inward/record.url?scp=0036790636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036790636&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(02)04380-0

DO - 10.1016/S0002-9270(02)04380-0

M3 - Article

C2 - 12385438

AN - SCOPUS:0036790636

VL - 97

SP - 2553

EP - 2558

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -